Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus

NCT05556291 is registered in ClinicalTrials.gov with Getz Pharma as lead sponsor.

NCT NCT05556291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05556291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus
Lead sponsor
Getz Pharma
Phase
Observational
Overall status
Completed
Start date
December 1, 2022
Completion date
December 1, 2024
Enrollment
190 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, safety, tolerability